Inhibition of Tumor Growth and Metastasis by Newcastle Disease Virus Strain P05 in a Breast Cancer Mouse Model

Ortega-Rivera, Oscar A; Gallegos-Alcalá, Pamela; Jiménez, Mariela; Quintanar, J. Luis; Torres-Juárez, Flor; Rivas-Santiago, Bruno; Toro-Arreola, Susana del; Salinas, Eva

doi:10.4048/jbc.2023.26.e9

Cited by 2 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…delivered oncolytic viruses are effective, especially as compared to systemic treatment. A recombinant Newcastle disease virus (NDV) virus strain 5 (rNDV-P05) was delivered to 4T1murine tumors thrice, spaced a week apart ( 107 ). No effect was observed, though the systemic administration of the virus did yield an anti-tumor effect ( 107 ).…”

Section: Preclinical Studiesmentioning

confidence: 99%

Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies

Mantooth,

Abdou,

Saez-Ibañez

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Breast cancer poses one of the largest threats to women’s health. Treatment continues to improve for all the subtypes of breast cancer, but some subtypes, such as triple negative breast cancer, still present a significant treatment challenge. Additionally, metastasis and local recurrence are two prevalent problems in breast cancer treatment. A newer type of therapy, immunotherapy, may offer alternatives to traditional treatments for difficult-to-treat subtypes. Immunotherapy engages the host’s immune system to eradicate disease, with the potential to induce long-lasting, durable responses. However, systemic immunotherapy is only approved in a limited number of indications, and it benefits only a minority of patients. Furthermore, immune related toxicities following systemic administration of potent immunomodulators limit dosing and, consequently, efficacy. To address these safety considerations and improve treatment efficacy, interest in local delivery at the site of the tumor has increased. Numerous intratumorally delivered immunotherapeutics have been and are being explored clinically and preclinically, including monoclonal antibodies, cellular therapies, viruses, nucleic acids, cytokines, innate immune agonists, and bacteria. This review summarizes the current and past intratumoral immunotherapy clinical landscape in breast cancer as well as current progress that has been made in preclinical studies, with a focus on delivery parameters and considerations.

show abstract

Section: Preclinical Studiesmentioning

confidence: 99%